ALT241115P18000
- 0.00
- 0.000.00%
Altimmune Newsroom
Altimmune Analyst Ratings
H.C. Wainwright Maintains Altimmune(ALT.US) With Buy Rating, Maintains Target Price $12
Altimmune's Pemvidutide Progress and Expansion: A Buy Recommendation by Patrick Trucchio
Evercore Maintains Altimmune(ALT.US) With Buy Rating, Maintains Target Price $25
B.Riley Financial Maintains Altimmune(ALT.US) With Buy Rating, Maintains Target Price $20
Altimmune Analyst Ratings
UBS Initiates Altimmune(ALT.US) With Buy Rating, Announces Target Price $26
Altimmune's Pemvidutide: A Promising Buy Rating for Metabolic Health Breakthroughs
Evercore Maintains Altimmune(ALT.US) With Buy Rating, Maintains Target Price $25
Analysts Are Bullish on Top Healthcare Stocks: Altimmune (ALT), Hansa Biopharma AB (SE:HNSA)
Piper Sandler Maintains Altimmune(ALT.US) With Buy Rating, Maintains Target Price $25
Analysts Offer Insights on Healthcare Companies: Abbott Laboratories (ABT), Altimmune (ALT) and Steris (STE)
JMP Securities Maintains Altimmune(ALT.US) With Buy Rating, Maintains Target Price $24
JMP Securities Maintains Altimmune(ALT.US) With Buy Rating, Maintains Target Price $24
JMP Securities Maintains Altimmune(ALT.US) With Buy Rating, Maintains Target Price $24
Buy Rating Affirmed for Altimmune on Pemvidutide's Positive Trial Data and Strategic Advancements
HC Wainwright & Co. Reiterates Buy on Altimmune, Maintains $12 Price Target
Altimmune Analyst Ratings
H.C. Wainwright Maintains Altimmune(ALT.US) With Buy Rating, Maintains Target Price $12
Optimistic Buy Rating for Altimmune's Pemvidutide on Promising Clinical and Strategic Developments